niacinamide has been researched along with Metabolic Syndrome in 5 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The presence of overweight/obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, and of the MS itself did not impair the median OS." | 5.48 | Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. ( Galle, PR; Huber, Y; Koch, S; Labenz, C; Marquardt, JU; Prenosil, V; Schattenberg, JM; Weinmann, A; Wörns, MA, 2018) |
| "The metabolic syndrome is an increasing etiology of HCC and carcinogenesis in this context may not always require the development of formal underlying cirrhosis." | 2.46 | Hepatocellular carcinoma--what's new? ( Barbare, JC; Belghiti, J; Castaing, D; Chirica, M; Farges, O; Paradis, V; Soubrane, O; Vullierme, MP, 2010) |
| "The presence of overweight/obesity, type 2 diabetes mellitus, hypertension, dyslipidemia, and of the MS itself did not impair the median OS." | 1.48 | Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. ( Galle, PR; Huber, Y; Koch, S; Labenz, C; Marquardt, JU; Prenosil, V; Schattenberg, JM; Weinmann, A; Wörns, MA, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sambeat, A | 1 |
| Ratajczak, J | 1 |
| Joffraud, M | 1 |
| Sanchez-Garcia, JL | 1 |
| Giner, MP | 1 |
| Valsesia, A | 1 |
| Giroud-Gerbetant, J | 1 |
| Valera-Alberni, M | 1 |
| Cercillieux, A | 1 |
| Boutant, M | 1 |
| Kulkarni, SS | 1 |
| Moco, S | 1 |
| Canto, C | 1 |
| Villeda-González, JD | 1 |
| Gómez-Olivares, JL | 1 |
| Baiza-Gutman, LA | 1 |
| Manuel-Apolinar, L | 1 |
| Damasio-Santana, L | 1 |
| Millán-Pacheco, C | 1 |
| Ángeles-Mejía, S | 1 |
| Cortés-Ginez, MC | 1 |
| Cruz-López, M | 1 |
| Vidal-Moreno, CJ | 1 |
| Díaz-Flores, M | 1 |
| Labenz, C | 1 |
| Prenosil, V | 1 |
| Koch, S | 1 |
| Huber, Y | 1 |
| Marquardt, JU | 1 |
| Schattenberg, JM | 1 |
| Galle, PR | 1 |
| Weinmann, A | 1 |
| Wörns, MA | 1 |
| Vullierme, MP | 1 |
| Paradis, V | 1 |
| Chirica, M | 1 |
| Castaing, D | 1 |
| Belghiti, J | 1 |
| Soubrane, O | 1 |
| Barbare, JC | 1 |
| Farges, O | 1 |
| Asadullaev, MM | 1 |
| Saidvaliev, FS | 1 |
| Shermukhamedova, FK | 1 |
| Rizvonov, ZhK | 1 |
| Vakhabova, NM | 1 |
1 review available for niacinamide and Metabolic Syndrome
| Article | Year |
|---|---|
Hepatocellular carcinoma--what's new?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neop | 2010 |
1 trial available for niacinamide and Metabolic Syndrome
| Article | Year |
|---|---|
[Assessment of multimodal effect of cytoflavin in the acute brain stroke in patients with metabolic syndrome].
Topics: Administration, Intravenous; Aged; Antioxidants; Drug Combinations; Female; Flavin Mononucleotide; H | 2012 |
3 other studies available for niacinamide and Metabolic Syndrome
| Article | Year |
|---|---|
Endogenous nicotinamide riboside metabolism protects against diet-induced liver damage.
Topics: Animals; Blood Glucose; Diet, High-Fat; Disease Models, Animal; DNA Damage; Gene Knockout Techniques | 2019 |
Nicotinamide reduces inflammation and oxidative stress via the cholinergic system in fructose-induced metabolic syndrome in rats.
Topics: Acetylcholinesterase; Animals; Anthropometry; Anti-Inflammatory Agents; Aryldialkylphosphatase; Buty | 2020 |
Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, | 2018 |